Pfizer Inc. (NYSE:PFE) is undervalued, with promising results from the EMBARK study on XTANDI for prostate cancer. The company focuses on biopharmaceuticals, offering potential as an investment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing